Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gastrointestinal 1CNS 1Breast 1

Conditions

Glioblastoma 5Neoplasms 2Brain Neoplasms 2Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Gliosarcoma 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 126Cisplatin 48Cetuximab 46Nivolumab 36Carboplatin 33Paclitaxel 28Fluorouracil 26Docetaxel 17Cyclophosphamide 12avelumab 11Radiotherapy 11cemiplimab 10atezolizumab 10durvalumab 9Ipilimumab 8spartalizumab 7fludarabine 7budigalimab 7Gemcitabine 7Capecitabine 7tremelimumab 6lenvatinib 6Pemetrexed 6130-nm albumin-bound paclitaxel 6epacadostat 5Fulvestrant 5zimberelimab 4tislelizumab 4Trastuzumab 4Oxaliplatin 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Squamous Cell Carcinoma of Head and Neck × depatuxizumab mafodotin × Clear all
NCT02365662 2018-03-30

A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor

AbbVie

Phase 1 Terminated
46 enrolled
BreastCNSGastrointestinalHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Glioblastoma, Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡